Clinical Trials

28 trials
RecentStart dateEnrollment
OTHER × Paraproteinemias × Clear all
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Anus Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Duodenal Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Hypopharyngeal Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Lip Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Multiple Myeloma, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Paraproteinemias, Penile Neoplasms, Peritoneal Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Central Nervous System Neoplasms, Thyroid Nodule, Endometrial Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
117 enrolled 27 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Paraproteinemias, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Hellenic Society of Hematology

Phase 1/2 Not yet recruiting
48 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell